Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET)

Status Not yet recruiting

Clinical Trial Summary

Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall survival (OS) ranged from 15 to 18 months. Some frail patients received hypofractionated radiation and concomitant and adjuvant TMZ. For some, the radiation dose is not optimal. Moreover, recurrences develop mainly in the initial tumor site. These two reasons justify increasing the dose. To limit the movements of these fragile patients, the method consists of increasing the dose without increasing the number of sessions by using the Simultaneous Integrated Boost (SIB) which increases the dose in targeted volumes while the rest of the volume receives a minimum dose. A phase I trial showed the possibility of increasing the dose in SIB up to 80 Gy in a part of the GBM enhanced on MRI. FDOPA PET detects certain more aggressive tumor areas, areas likely to recur. Integrating them into the SIB seems appropriate. A phase II trial showed the interest of SIB guided by FDOPA PET in terms of progression-free survival but without impact on OS. This study differed from the one the investigators propose, because a dose and conventional fractionation, identical to that of the European Organization for Research and Treatment of Cancer/National Cancer Information Center (NCIC/EORTC) protocol were delivered, the gliomas were unmethylated MGMT, less likely to respond. Studies with SIB and hypofractionation are often retrospective and for others, hypofractionation was debatable and the dose increase was not based on PET capture but on MRI. However, a prospective phase II study, with SIB and hypofractionation, not integrating FDopa PET has demonstrated the relevance of SIB. In this project, the investigators propose to use the integrated boost technique (SIB) guided by PET FDOPA to increase the radiation dose in GBM, in patients either fragile and partially operated, or only biopsied and for whom the prognosis is the most pejorative.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05653622
Study type	Interventional
Source	Institut de cancérologie Strasbourg Europe
Contact	Manon VOEGELIN
Phone	+33(0)368339523
Email	m.voegelin@icans.eu
Status	Not yet recruiting
Phase	Phase 2
Start date	March 1, 2023
Completion date	March 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04762069` - A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme	Phase 2
Recruiting	`NCT04869449` - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas	Early Phase 1
Withdrawn	`NCT03480867` - Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)	Phase 1
Recruiting	`NCT05954858` - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma	N/A
Recruiting	`NCT05052957` - hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)	Phase 2
Recruiting	`NCT05977738` - Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin	Early Phase 1
Recruiting	`NCT04614909` - Study of Pamiparib in Newly Diagnosed and rGBM	Early Phase 1
Recruiting	`NCT06146725` - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting	`NCT06146738` - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting	`NCT06283927` - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting	`NCT06118723` - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting	`NCT04825275` - Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial	Early Phase 1
Recruiting	`NCT05333588` - The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.	Early Phase 1
Recruiting	`NCT05565521` - UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly	Phase 2
Completed	`NCT05671016` - Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy
Recruiting	`NCT05271240` - Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM	Phase 3
Recruiting	`NCT04469699` - Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma	Phase 2
Recruiting	`NCT05720078` - UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma — SIB-DOPA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms